Ipsen Secures Exclusive Rights for Sutro’s Antibody-Drug Conjugate (ADC) Portfolio in a $900 Million Agreement

1. Ipsen, a pharmaceutical company, has entered into an agreement with Sutro, securing exclusive rights to their antibody-drug conjugates (ADC).
2. The deal is worth up to $900 million, with approximately $90 million paid immediately by Ipsen.
3. This partnership was announced four days ago as of the current date, which is Saturday, April 6, 2024.
4. The news has been shared across various platforms such as Endpoints News, Twitter, San Francisco Biotechnology Network, LinkedIn, and RAPS.